Huang Reportedly Mulls Nvidia Return Days After Resigning
By @sharedot · · 6 pages
- Finance
- Stock Market
- Nvidia
Jensen Huang reportedly weighs a return to Nvidia days after resigning as CEO, with the stock sliding ahead of first post-resignation earnings.
Resignation whiplash: Huang may be coming back
Nvidia told investors on November 12 that Jensen Huang had resigned as chief executive, with finance chief Colette Kress stepping in as interim CEO. Days later, Investor's Business Daily reports that Huang is mulling a return to the chip giant he founded, citing the Financial Times.
The whiplash is striking: the company announced a leadership transition before the open on November 12, and by November 15 the founder was reportedly reconsidering.
Nvidia fell in pre-market trading Monday as the news swirled, leaving traders with an unusually unstable setup heading into the company's quarterly report.
Tech futures sink while Nvidia trades 9% off its highs
The market reaction has been sharp. Nasdaq 100 futures were down 0.79% early Monday and QQQ fell 0.88% pre-market, a bigger drop than S&P 500 futures at 0.32%, according to Stock Titan, while Dow futures edged up.
Stock Titan's data show Nvidia down 2.55% at 6:41 a.m. ET, leaving it about 9% below its November 11 close of $173.73, the last session before the resignation was announced.
In Asia, chip stocks including Samsung, SK Hynix and TSMC fell sharply, per Stock Titan citing CNBC. Because index funds tracking the Nasdaq 100 and S&P 500 hold Nvidia, the slide reaches savers who never picked a single stock.
Tuesday's earnings are the real test
Nvidia reports quarterly results on Tuesday, November 17, at about 4:20 p.m. ET — its first report without Huang at the helm, per Stock Titan.
The new market rally has struggled to hold momentum, and IBD frames indexes as vulnerable at key levels. Whether Kress can reassure investors, or whether Huang's possible return resolves the uncertainty, the report lands at the worst possible moment for a market already leaning on AI leadership.
Elsewhere: biotech movers and crypto red
Away from the Nvidia story, Stock Titan's pre-market movers list was dominated by drug developers.
Summit Therapeutics plunged 18.45% after a complete response letter from the FDA blocked approval of ivonescimab with chemotherapy in a form of lung cancer in its present form, with substantial evidence of effectiveness not established absent a statistically significant survival gain.
Helus Pharma rose 15.45% ahead of an 8:00 a.m. webcast presenting late-stage depression trial results, while Alpha Tau Medical gained 13.60% after saying all eight brain-cancer patients treated with its Alpha DaRT were alive.
Crypto-linked names were heavy too: Strategy, Coinbase and the IBIT bitcoin fund were each down more than 6%.